Currently, numerous IL-17-targeted inhibitors have been approved for the treatment of autoimmune diseases such as psoriasis, rheumatoid arthritis, and ankylosing spondylitis or for those that have advanced to phase III clinical trials. The gene discussed is IL17A; the disease is autoimmune disease.